Goodwin‘s broad geographical coverage in the US captures deals from across regions and industries. It remains highly active in biotech and life sciences equity offerings, along with further strength in healthcare, real estate and technology. It also has an extensive client base of investment banks. Although the IPO markets were quiet in 2023, the firm remained active in follow-on offerings, PIPEs, private placements and at-the-market programs. It is best known for mid-cap deals, though does handle bulge-bracket transactions. New York-based Edwin O’Connor is a member of the life sciences group and co-chair of the capital markets practice alongside Silicon Valley's Bradley Weber. Boston-based Joseph Theis and Robert Puopolo are noted for technology, healthcare and life sciences sector deals.
Key clients
- TIP Composites, Inc.
- SkyWater Technologies
- NAPCO Security Technologies
- Nutrabolt
- Amylyx Pharmaceuticals
- Credit Suisse
- Boston Properties
- Avadel Pharmaceuticals
- Akero Therapeutics
- BridgeBio Pharma
- Sagimet Biosciences
- Argenx SE
Work highlights
- Advised argenx on the closing of its upsized $1.27bn global offering.
- Advised Avadel Pharmaceutics in three major transactions including a $125m follow-on equity offering, a $96m exchange of convertible notes and a $75m royalty financing.
- Advised Woodbolt Holdings in their equity investment with Keurig Dr Pepper, involving a cash investment in Nutrabolt of $863m in exchange for preferred equity with a 5% annual coupon paid in cash or in-kind.
Practice head
The lawyer(s) leading their teams.
Edwin O’Connor, Bradley Weber, James Barri